ANAPHYLAXIS PRESCRIBER ORDER FORM						
Patient Name:				Date o	f Birth:	
Address:					Weight:	□ lbs □ kg
	Anaphylaxis Kit					
PATIENT WEIGHT	MEDICATION	DOSAGE		ADMINISTRATION INFORMATION		
Adults & Pediatrics > 30 kg	Epinephrine 1 mL ampule/vial (1 mg/mL) #2 <u>or</u> *Epinephrine 0.3 mg auto-injector 2-pack kit #1	0.3 mg	IM or SUBQ x 1 dose & may repeat x 1 in 5 to 15 min PRN			
	0.9% Sodium Chloride 500 mL bag #1	500 mL	KVO rate PRN anaphylaxis			
	Diphenhydramine 1 mL (50 mg/mL) vial #1	25 mg	Slow IV push (if line patent) or IM; may repeat x 1 in 15 min PRN if no improvement			
Pediatrics 15 to 30 kg	Epinephrine 1 mL ampule/vial (1 mg/mL) #2 <u>or</u> *Epinephrine 0.15 mg auto-injector 2-pack kit #1	0.15 mg	IM or SUBQ x 1 dose & may repeat x 1 in 5 to 15 min PRN			
	0.9% Sodium Chloride 250 mL bag #1	250 mL	KVO rate PRN anaphylaxis			
	Diphenhydramine 1 mL (50 mg/mL) vial #1	1.25 mg/kg (25 mg max per dose)	Slow IV push (if line patent) or IM; may repeat x 1 in 15 min PRN if no improvement			
Pediatrics < 15 kg	Epinephrine 1 mL ampule/vial (1 mg/mL) #2	0.01 mg/kg	IM or SUBQ x 1 dose & repeat x 1 in 5 to 15 min PRN			
	0.9% Sodium Chloride 250 mL bag #1	250 mL	KVO rate PRN anaphylaxis			
	Diphenhydramine 1 mL (50 mg/mL) vial #1	1.25 mg/kg	Slow IV push (if line patent) or IM; may repeat x 1 in 15 min PRN if no improvement			
· · · · ·	to administer aforementioned medications, including plobulin patients, only epinephrine auto-injector 2-pace Anaphylaxis Management for All IV Medication	ck kits will be di	spensed.	Immun	e Globulin	
<ol> <li><u>Srop</u> the infusion of 2. Contact or have ca</li> <li>Administer epinep</li> <li>Administer epinep</li> <li>Administer epinep</li> <li>Monitor and documelevated or in Trent</li> <li>Maintain IV line with</li> <li>Contact the prescribility</li> <li>Contact the prescribility</li> <li>Monitor and document</li> <li>Contact the prescribility</li> <li>Monitor and document</li> <li>Remain with patie</li> <li>Subcutaneous Immune Globot</li> <li>Call 911.</li> <li>Administer epinep</li> <li>Notify prescriber and</li> <li>When appropriate, nurse shall</li> </ol>	<ul> <li>e, for <u>SEVERE</u> reactions including angioedema, wheezin of the medication immediately. Completely remove the regiver call 911.</li> <li>hrine as above and may repeat dose if necessary.</li> <li><u>ble</u> diphenhydramine (Benadryl®) as above.</li> <li>ment patient's vital signs, including mental status. If I nealenburg position. If breathing difficulty, tilt the patither and Option Care Health Director of Nursing or phy arrest occurs, begin CPR.</li> <li>ment vital signs every 2 minutes until stable, then even nt until paramedics arrive.</li> <li>ulin Anaphylaxis – For <u>SEVERE</u> reactions such as wheezed of the medication immediately and remove the needle hrine for one dose as above, repeat dose if necessary and Option Care Health Director of Nursing or pharma</li> <li>Il instruct patient/caregiver about the signs/symptom cian order shall be recognized for the patient's period.</li> </ul>	he source of the hypotensive, pl tient's head or keep line open harmacist. ery 15 minutes a <i>cing, difficulty in</i> es from the skir <i>r</i> , acist. as of allergic, an	e infusate whil ace the patien thrust jaw to r until the arriva as needed. as needed. breathing, or n. aphylactic, and	le maint nt in sup relieve a al of a p <i>swellin</i> d adver	taining venous ine position w airway obstruc aramedic or a g of eye lids, li se reactions a	s access. with lower extremities tion. mbulance.
I certify	that the use of the indicated treatment is medically r	necessary, and I	will be superv	vising th	e patient's tre	atment.
Prescriber Signature:		Date:				
Prescriber Information Prescriber Name: NPI:						
Fax completed form, insurance information, and clinical documentation to:						
CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure of failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is intended for the entender recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRCTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.						